In reply: The guidelines were published to provide clinicians with the most contemporary information on the management of acute coronary syndromes based on the international literature, and may include treatments which are not currently available, officially licensed or available through the Pharmaceutical Benefits Scheme in Australia.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
We are consultants for, advisory committee members of, or receive honoraria, fees for service, or travel assistance (independent of research-related meetings) from, or have research or other associations with the organisations listed: Constantine Aroney — CSL, Merck Sharpe & Dohme, Sanofi-Aventis; Phil Aylward — Sanofi-Aventis, Pfizer, Merck Sharpe & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Procter & Gamble, Eli Lilly, The Medicines Co, Servier, CSL, Schering Plough.